论文部分内容阅读
目的:评价肺表面活性物质(PS)治疗婴幼儿体外循环后急性呼吸窘迫综合征(ARDS)的有效性。方法:选取ARDS的婴幼儿患者20例,随机均分成2组。2组均常规治疗,治疗组加用PS,观察2组临床疗效。结果:治疗组死亡率明显比对照组低(P<0.05),有效率比较差异有统计学意义(P<0.05)。治疗组肺动态顺应性和氧合指数明显改善(P<0.05),机械通气时间和ICU住院时间明显缩短(P<0.05)。结论:PS可有效治疗体外循环后ARDS。
PURPOSE: To evaluate the effectiveness of pulmonary surfactant (PS) in the treatment of acute respiratory distress syndrome (ARDS) after cardiopulmonary bypass in infants and young children. Methods: Twenty infants and young children with ARDS were randomly divided into two groups. The two groups were treated routinely, the treatment group plus PS, observed the clinical efficacy of the two groups. Results: The mortality of the treatment group was significantly lower than that of the control group (P <0.05), and the difference of the effective rate was statistically significant (P <0.05). The pulmonary dynamic compliance and oxygenation index of the treatment group were significantly improved (P <0.05), and the duration of mechanical ventilation and hospital stay were significantly shorter (P <0.05). Conclusion: PS can effectively treat ARDS after cardiopulmonary bypass.